04/14/2026
WPS Oncology Related LCD Updates
New Policy Updates
April 2026 Local Coverage Determination (LCD) and Billing and Coding Article Updates
We updated the following Local Coverage Determinations (LCDs) and Billing and Coding Articles for April 2024. The full article on our website details additional information on these updates.
Please note: Our LCDs and Billing and Coding/Coverage articles will reflect these changes on March 26, 2026.
New Policies/Articles – We created no new policies/articles for April 2026.
Retired Policies/Articles – We retired no policies/articles for April 2026.
Revised Policies/Articles – We revised the following policies/articles for Effective as Indicated
- Billing and Coding: Botulinum Toxin Injections – Effective March 5, 2026
- Billing and Coding: Immune Globulins – Effective March 26, 2026
- Billing and Coding: MolDx: Minimal Residual Disease Testing for Solid Tumor Cancers – Effective March 12, 2026
- Billing and Coding: MolDx: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing – Effective March 12, 2026
- Billing and Coding: Non-Invasive Abdominal / Visceral Vascular Studies – Effective March 26, 2026
- Billing and Coding: Pelvic Floor Dysfunction: Anorectal Manometry and EMG – Effective March 5, 2026
- Billing and Coding: Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC)– Effective March 1, 2026
- Billing and Coding: Urine Drug Testing – Effective March 26, 2026
- Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC – Effective March 1, 2026